A historical cohort study to assess the safety and effectiveness of olaparib monotherapy in patients with platinum-sensitive relapsed ovarian cancer
Not Applicable
- Conditions
- Ovarian cancer
- Registration Number
- JPRN-UMIN000041422
- Lead Sponsor
- Japanese Gynecologic Oncology Group (JGOG)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- Female
- Target Recruitment
- 471
Inclusion Criteria
Not provided
Exclusion Criteria
1. platinum-resistant relapsed ovarian cancer 2. stable or progressive disease after platinum-based chemotherapy for patients with platinum-sensitive relapsed ovarian cancer 3. patients who had already received a PARP inhibitor before recurrence 4. patients who received both olaparib and bevacizumab combination maintenance therapy.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method